Analytical Data
-
Gene name
LINGO1
- Application
-
Alternative Names
Leucine-rich repeat neuronal protein 1Leucine-rich repeat neuronal protein 6A
-
Species
Mouse
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9D1T0
-
Expression Region
37-555aa
-
Molecular Weight
60.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LINGO1 (Leucine-rich repeat and Ig-like domain-containing NOGO receptor-interacting protein 1) is a protein that has garnered significant attention in neuroscience and regenerative medicine due to its potential roles in axon growth inhibition and neural regeneration. Initially identified as an interacting partner of Nogo receptor, LINGO1 is believed to be involved in processes that regulate nervous system development and repair mechanisms following injury. Research has indicated that LINGO1 functions as a negative regulator of axonal regeneration, impacting the signaling pathways associated with myelin-associated inhibitors. This has led to an interest in developing LINGO1-targeted therapies to promote neural repair in conditions like spinal cord injuries and neurodegenerative diseases. Moreover, studies have linked LINGO1 to various neuropsychiatric disorders, suggesting that understanding its function and the modulation of its expression could have broader implications for mental health. Efforts to characterize and produce recombinant LINGO1 protein provide valuable insights into its structure-function relationship and facilitate the exploration of its therapeutic potential. The ongoing research into LINGO1 emphasizes its significance in advancing our understanding of neural communication and regeneration, positioning it as a promising target for interventions aimed at enhancing neural recovery and treating related disorders.
